Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for Crinetics Pharmaceuticals (CRNX) over the last 3 years, with Q4 2024 value amounting to $9.8 million.

  • Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability fell 48.98% to $9.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $9.8 million, marking a year-over-year decrease of 48.98%. This contributed to the annual value of $9.8 million for FY2024, which is 48.98% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Non-Current Deferred Tax Liability of $9.8 million as of Q4 2024, which was down 48.98% from $9.8 million recorded in Q4 2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $9.8 million in Q4 2023 and a low of $453000.0 during Q4 2022
  • Its 3-year average for Non-Current Deferred Tax Liability is $6.7 million, with a median of $9.8 million in 2024.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first surged by 206313.47% in 2023, then crashed by 48.98% in 2024.
  • Quarter analysis of 3 years shows Crinetics Pharmaceuticals' Non-Current Deferred Tax Liability stood at $453000.0 in 2022, then skyrocketed by 2063.13% to $9.8 million in 2023, then fell by 0.49% to $9.8 million in 2024.
  • Its Non-Current Deferred Tax Liability was $9.8 million in Q4 2024, compared to $9.8 million in Q4 2023 and $453000.0 in Q4 2022.